Predictors of Appropriate Pharmacotherapy Management of COPD Exacerbations and Impact on 6-Month Readmission.
BACKGROUND
Suboptimal treatment of exacerbations is a major concern in management of chronic obstructive pulmonary disease (COPD). The Pharmacotherapy Management of COPD Exacerbation (PCE) Healthcare Effectiveness Data and Information Set (HEDIS) measure is a quality measure included by the National Committee for Quality Assurance that focuses on appropriate use of steroids and bronchodilators during an acute COPD exacerbation. There is limited evidence evaluating predictors of this quality measure, as well as its association with hospital readmission and cost outcomes.


OBJECTIVE
To (a) describe characteristics of patients hospitalized for COPD, (b) evaluate factors associated with appropriate receipt of pharmacotherapy upon discharge, and (c) evaluate factors associated with the rate of readmission.


METHODS
In this retrospective, observational, event-based study of COPD-related hospital and ED visits, events were identified between 2007 and 2013 from a Central Texas health plan using administrative claims data. The index date was defined as the date of admission. Subjects were included if they were aged ≥ 40 years and had a medical claim with a primary diagnosis for COPD or a pharmacy claim for a COPD maintenance medication during the 1-year pre-index period. Study groups were identified based on the receipt of PCE within the time frame specified by HEDIS: (a) a systemic corticosteroid within 14 days of discharge (PCE-C) or (b) a bronchodilator within 30 days of discharge (PCE-D). Bivariate analyses of potential factors associated with the receipt of PCE were performed using t-tests for continuous data and chi-square tests for categorical data. Generalized estimating equations, including significant predictors from the bivariate analyses, were used to determine factors associated with receipt of PCE-C and/or PCE-D, as well association with COPD-related and all-cause readmission within 6 months of discharge.


RESULTS
Of 375 identified index admissions, 254 (68%) patients received PCE-C; 299 (80%) received PCE-D; and 229 (61%) received both. Patients were more likely to receive PCE with an index inpatient visit as compared with an ED visit (PCE-C: RR = 2.25, 95% CI = 1.21-4.17, P = 0.010; PCE-D: RR = 1.90, 95% CI = 1.01-3.58, P = 0.048). Those with previous use of rescue medication were also more likely to receive PCE (PCE-C: RR = 1.88, 95% CI = 1.12-3.17, P = 0.018; PCE-D: RR = 2.11, 95% CI = 1.16-3.83, P = 0.014). Patients with greater adherence (proportion of days covered [PDC] ≥ 75%) to COPD maintenance medication before admission (RR = 8.67, 95% CI = 1.60-46.78, P = 0.012) were also more likely to receive PCE-D. Older patients were more likely to have a COPD-related readmission (RR = 1.07, 95% CI = 1.01-1.13, P = 0.028), while use of maintenance medication before admission was associated with lower risk of an all-cause readmission (RR = 0.49, 95% CI = 0.30-0.79, P = 0.004). In addition, patients with higher medical and pharmacy costs before the index event were more likely to have all-cause readmission (RR = 1.01, 95% CI = 1.00-1.02, P = 0.013). Receipt of PCE was not shown to be a significant predictor of all-cause or COPD-related readmission.


CONCLUSIONS
The use of bronchodilators and systemic corticosteroids after a COPD-related inpatient or ED visit may be related to the severity of the index COPD exacerbation or patients' previous pattern of bronchodilator use. However, the use of maintenance medication before the index event was associated with a significant reduction in all-cause readmission, so proper treatment of the underlying disease may be an effective strategy in reducing readmission.


BACKGROUND
Funding for this study was provided by GlaxoSmithKline (HO-14-15081). Tran was a Fellow at Scott & White Health Plan (SWHP) during year 1 of this study and a Fellow at Novartis during year 2 of this study. Novartis did not have any input in this study nor did it contribute any funding or support for this research. Tran, Xiang, Godley, and Stock were employed by SWHP at the time of this study. Rascati is employed by the University of Texas at Austin and also by the Journal of Managed Care & Specialty Pharmacy and has received consulting fees from GlaxoSmithKline. Coleman, Bogart, and Stanford are GlaxoSmithKline employees and shareholders. Study design was created by Rascati, Tran, and Godley, with assistance from Stock, Coleman, Bogart, and Stanford. Tran and Xiang collected the data, with data analysis and interpretation performed by Stock and Rascati. The manuscript was written by Tran, Rascati, and Xiang and revised by Godley, Stock, Coleman, Bogart, and Stanford.
1 Scott & White Health Plan, Temple, Texas, and University of Texas at Austin College of Pharmacy, Austin, Texas.
Melody
M
Tran
1 Scott & White Health Plan, Temple, Texas, and University of Texas at Austin College of Pharmacy, Austin, Texas.
Pin
P
Xiang
2 University of Texas at Austin College of Pharmacy, Austin, Texas.
Karen L
KL
Rascati
1 Scott & White Health Plan, Temple, Texas, and University of Texas at Austin College of Pharmacy, Austin, Texas.
Eileen M
EM
Stock
1 Scott & White Health Plan, Temple, Texas, and University of Texas at Austin College of Pharmacy, Austin, Texas.
Paul J
PJ
Godley
3 GlaxoSmithKline, Research Triangle Park, North Carolina.
Amber
A
Coleman
3 GlaxoSmithKline, Research Triangle Park, North Carolina.
Michael R
MR
Bogart
3 GlaxoSmithKline, Research Triangle Park, North Carolina.
Richard H
RH
Stanford
D000367:Age Factors; D001993:Bronchodilator Agents / Q000627:therapeutic use; D016527:Drug Costs; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D054539:Medication Therapy Management / Q000592:standards*; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data; D010359:Patient Readmission / Q000706:statistics & numerical data; D010361:Patients; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications* / Q000188:drug therapy*; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D013781:Texas; D016896:Treatment Outcome
D001993:Bronchodilator Agents; D013256:Steroids
Int J Chron Obstruct Pulmon Dis. 2015 Feb 24;10:415-22
25759574
Ann Intern Med. 2005 Sep 6;143(5):317-26
16144890
Int J Chron Obstruct Pulmon Dis. 2010 Oct 05;5:341-9
21037958
Eur Respir Rev. 2010 Jun;19(116):113-8
20956179
Hosp Pract (1995). 2015;43(4):199-207
26357878
Ann Intern Med. 2006 Jun 20;144(12):894-903
16785478
Chest. 2015 Jan;147(1):31-45
25058738
Am J Manag Care. 2012 Sep 01;18(9):e338-45
23009332
Int J Chron Obstruct Pulmon Dis. 2011;6:533-42
22069365
Int J Chron Obstruct Pulmon Dis. 2012;7:1-9
22315517
Lancet. 2009 Oct 3;374(9696):1171-8
19716598
Int J Chron Obstruct Pulmon Dis. 2012;7:757-64
23152680
Int J Chron Obstruct Pulmon Dis. 2013;8:551-9
24348031
MMWR Morb Mortal Wkly Rep. 2012 Nov 23;61(46):938-43
23169314
N Engl J Med. 2007 Feb 22;356(8):775-89
17314337
J Chronic Dis. 1987;40(5):373-83
3558716